Results 1 to 10 of about 1,162 (187)
Carbohydrate Mimetic Peptides for Pan Anti-Tumor Responses
Frontiers in Immunology, 2014 Molecular mimicry is fundamental to biology which transcends to many disciplines ranging from immune pathology to drug design. Structural characterization of molecular partners has provided insight into the origins and relative importance of ...
Thomas eKieber-Emmons +4 more
doaj +2 more sources
Altered Glycosylation in Progression and Management of Bladder Cancer
Molecules, 2023 Bladder cancer (BC) is the 10th most common malignancy worldwide, with an estimated 573,000 new cases and 213,000 deaths in 2020. Available therapeutic approaches are still unable to reduce the incidence of BC metastasis and the high mortality rates of ...
Magdalena Wilczak +2 more
doaj +1 more source
A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes. [PDF]
PLoS ONE, 2017 Single-agent immunotherapy is ineffective against poorly immunogenic cancers, including pancreatic ductal adenocarcinoma (PDAC). The aims of this study were to demonstrate the feasibility of production of novel autologous tumor lysate vaccines from ...
Kenta Furukawa +15 more
doaj +1 more source
Carbohydrate antigen 15-3 as a marker of disease severity in patients with chronic hypersensitivity pneumonitis* [PDF]
Jornal Brasileiro de PneumologiaObjective: Biomarkers associated with mucin 1, such as Krebs von den Lungen-6 and carbohydrate antigen (CA) 15-3, are increased in various interstitial lung diseases.
Paula Silva Gomes +7 more
doaj +4 more sources
Conjugate Vaccines Targeting Tumor-Associated Carbohydrate Antigens
VaccinesThe surface of cancer cells is covered in abnormal carbohydrate antigens that facilitate tumor growth, immune evasion and metastasis. Overexpressed and often specific to cancer cells, these tumor-associated carbohydrate antigens (TACAs) offer a valuable ...
Nadine Rosenglick +4 more
doaj +1 more source
BMC Cancer, 2008 Background The number of breast cancer patients diagnosed with ductal carcinoma in situ (DCIS) continues to grow. Laboratory and clinical data indicate that DCIS can progress to invasive disease.
Kieber-Emmons Thomas +3 more
doaj +1 more source
Tumor-Associated Glycans and Immune Surveillance
Vaccines, 2013 Changes in cell surface glycosylation are a hallmark of the transition from normal to inflamed and neoplastic tissue. Tumor-associated carbohydrate antigens (TACAs) challenge our understanding of immune tolerance, while functioning as immune targets that
Anastas Pashov +2 more
doaj +1 more source
Biomedicines, 2023 Background: Suppressor of fused (SuFu) is a tumor-suppressor gene that regulates hedgehog signaling. Its involvement in some malignancies is broadly accepted. However, its association with colorectal cancer (CRC) pathogenesis is not clear.
Tahseen Bilal Rather +11 more
doaj +1 more source
State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
CellsChimeric antigen receptor (CAR)-T cell therapy has proven to be a powerful treatment for hematological malignancies. The situation is very different in the case of solid tumors, for which no CAR-T-based therapy has yet been approved.
Beatriz Amorós-Pérez +4 more
doaj +1 more source
MGL Receptor and Immunity: When the Ligand Can Make the Difference
Journal of Immunology Research, 2015 C-type lectin receptors (CLRs) on antigen-presenting cells (APCs) facilitate uptake of carbohydrate antigens for antigen presentation, modulating the immune response in infection, homeostasis, autoimmunity, allergy, and cancer.
Ilaria Grazia Zizzari +7 more
doaj +1 more source